膵臓がんの治療の世界市場

膵臓がんの治療の世界市場は2030年までに60億米ドルに達する見込み

2024年に32億米ドルと推定される膵臓がんの治療の世界市場は、2024～2030年の分析期間においてCAGR 11.2%で成長し、2030年には60億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである化学療法は、CAGR 9.5%を記録し、分析期間終了までに13億米ドルに達すると予想されます。免疫療法分野の成長率は、分析期間のCAGRで13.4％と推定されます。

米国市場は8億6,170万米ドルと推定、中国はCAGR14.9％で成長予測

米国の膵臓がんの治療市場は、2024年に8億6,170万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに12億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは14.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ8.3％と9.8％と予測されています。欧州では、ドイツがCAGR約8.8%で成長すると予測されています。

世界の膵臓がんの治療市場- 主要動向と促進要因まとめ

膵臓がんが最も課題であり急成長しているがん領域のひとつである理由とは？

膵がん、特に膵管腺がん（PDAC）は、5年生存率が10％未満という最も侵攻性の高い悪性腫瘍の1つです。初期症状や信頼できるスクリーニング手段がないため、進行した段階で診断されることが多いです。従来の化学療法に抵抗性があり、転移の進行が速いため、効果的な治療が最も困難ながんのひとつです。人口の高齢化、生活習慣、遺伝的素因によって罹患率が増加するにつれ、膵臓がんは世界の腫瘍学の主要な焦点となっています。

膵がんは歴史的に予後不良であるにもかかわらず、研究努力は強化されつつあり、この疾患の分子構造に対するより微妙な理解が新たな治療の道を開きつつあります。FOLFIRINOXやゲムシタビンをベースとしたレジメンなどの標準治療は依然として基礎的なものであるが、精密治療、免疫療法、標的生物学的製剤によって補完されつつあります。膵臓腫瘍における腫瘍生物学、緻密な間質環境、および免疫回避機構の複雑性から、マルチモーダルかつ適応的な治療戦略が必要です。緊急の臨床的ニーズは、国際的規模での技術革新、資金提供、共同研究の触媒となっています。

標的治療と診断の進歩は、どのように膵臓がんの治療Pathwayを変革するのか？

プレシジョン・オンコロジーは、膵臓がんの治療のゲームチェンジャーとして台頭してきています。BRCA変異腫瘍や相同組換え欠損（HRD）腫瘍はオラパリブなどのPARP阻害剤に反応し、KRAS G12C阻害剤は特定の変異サブタイプに対して臨床試験が行われています。腫瘍の分子プロファイリングは治療法の決定と患者選択を導き、より個別化された治療アプローチを可能にしています。免疫療法は、膵臓がんの腫瘍微小環境が"冷たい"ため、従来は効果がなかったが、チェックポイント阻害剤、間質調節、腫瘍溶解ウイルスを含む併用戦略によって再評価されつつあります。

診断面では、リキッドバイオプシー、循環腫瘍DNA（ctDNA）、エクソソームRNA分析により、早期発見とリアルタイムの疾患モニタリングが改善されつつあります。超音波内視鏡（EUS）ガイド下生検、次世代シークエンシング（NGS）、コンパニオン診断は、診断と治療計画の日常的な要素になりつつあります。精密診断と分子分類が普及するにつれ、膵臓がんの治療は遺伝的・エピジェネティックな要因が全身的・局所的介入を導く層別化モデルへと移行しつつあります。

膵がん治療の需要を形成している患者集団と地域市場は？

膵がんは主に60歳以上の患者が罹患し、女性よりも男性の方が若干リスクが高いです。家族性がん症候群、慢性膵炎、糖尿病、肥満、タバコ使用歴のある患者は特に罹患しやすいです。本疾患の攻撃的な性質と診断後の治療期間が限られていることから、腫瘍医、外科医、緩和ケア提供者を含む迅速な集学的治療プロトコルの重要性が強調されています。

北米と欧州は、先進的な診断法、臨床試験活動、併用レジメンへのアクセスという点でリードしています。米国は、強力な資金提供、学術研究協力、国家がん戦略への膵臓がんの組み入れにより、最先端を走っています。日本と韓国は、罹患率の増加と早期発見技術への強力な投資を目の当たりにしています。アフリカ、東南アジア、ラテンアメリカの一部などの開発途上地域では、膵がん治療へのアクセスが依然として限られており、モバイル診断、政府後援の検診、国際的な支援プログラムなどの機会が強調されています。

膵臓がんの治療市場の長期的成長と科学的イノベーションの原動力は？

膵臓がんの治療市場の成長の原動力は、疾病負担の増加、ゲノム理解の深化、治療抵抗性の克服に焦点を当てた研究開発の急増です。ドラッグデリバリー開発者は、抗体薬物複合体（ADC）、エピジェネティック・モジュレーター、T細胞エンゲイザー、ナノ粒子ベースのデリバリー・プラットフォームなどの新しい手法に投資しています。免疫療法の組み合わせ、新抗原を標的とするワクチン、間質を標的とする薬剤は、単剤療法試験では過去に失望させられたもの、臨床パイプラインでは有望視されています。

戦略的革新は、適応型臨床試験デザイン、バイオマーカー誘導型リクルートメント、国際共同治験ネットワークにおいても顕著です。製薬会社は、規制当局の承認を早め、市場での独占権を確保するために、ファスト・トラックや希少疾病用医薬品の指定を追求しています。官民パートナーシップはトランスレーショナルリサーチに資金を提供し、アドボカシー団体は認知度向上、早期スクリーニング、公平なアクセスを推進しています。個別化されたバイオマーカー主導の治療に向けて腫瘍学の展望が進展する中、膵がんは臨床上の大きな課題であると同時に、治療上のブレークスルーをもたらす可能性の高いフロンティアとして際立っています。

セグメント

治療タイプ（化学療法、免疫療法、ホルモン療法、外科療法、放射線療法、標的療法）、適応症タイプ（外分泌適応症、内分泌適応症）、エンドユーザー（病院エンドユーザー、オンコロジークリニックエンドユーザー、その他エンドユーザー）

調査対象企業の例（注目の合計42社）

• AstraZeneca plc
• Bayer AG
• Beigene Ltd.
• Bristol-Myers Squibb Company
• Celgene Corporation
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Genentech, Inc.
• GlaxoSmithKline plc
• Ipsen Pharma
• Lisata Therapeutics
• Merck & Co., Inc.
• Myriad Genetics, Inc.
• Novartis AG
• Oncolytics Biotech Inc.
• Pfizer Inc.
• PharmaCyte Biotech, Inc.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Zydus Cadila

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Pancreatic Cancer Treatment Market to Reach US$6.0 Billion by 2030

The global market for Pancreatic Cancer Treatment estimated at US$3.2 Billion in the year 2024, is expected to reach US$6.0 Billion by 2030, growing at a CAGR of 11.2% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 9.5% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the Immunotherapy segment is estimated at 13.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$861.7 Million While China is Forecast to Grow at 14.9% CAGR

The Pancreatic Cancer Treatment market in the U.S. is estimated at US$861.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 14.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.3% and 9.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.8% CAGR.

Global Pancreatic Cancer Treatment Market - Key Trends & Drivers Summarized

Why Is Pancreatic Cancer One of the Most Challenging and Rapidly Growing Oncology Segments?

Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), is one of the most aggressive malignancies with a five-year survival rate of less than 10%. It is often diagnosed at an advanced stage due to the lack of early symptoms and reliable screening tools. The disease’s resistance to conventional chemotherapy and rapid metastatic progression make it one of the most difficult cancers to treat effectively. As incidence rates increase-driven by aging populations, lifestyle factors, and genetic predispositions-pancreatic cancer has become a major focus in global oncology.

Despite its historically poor prognosis, research efforts are intensifying, and a more nuanced understanding of the disease’s molecular landscape is opening new therapeutic avenues. Standard treatments such as FOLFIRINOX and gemcitabine-based regimens remain foundational, but are increasingly being supplemented by precision therapies, immunotherapies, and targeted biologics. The complexity of tumor biology, dense stromal environment, and immune evasion mechanisms in pancreatic tumors necessitate multi-modal and adaptive treatment strategies. The urgent clinical need is catalyzing innovation, funding, and collaborative research on an international scale.

How Are Targeted Therapies and Diagnostic Advances Transforming Pancreatic Cancer Treatment Pathways?

Precision oncology is emerging as a game-changer in pancreatic cancer treatment. BRCA-mutated and homologous recombination deficient (HRD) tumors respond to PARP inhibitors such as olaparib, while KRAS G12C inhibitors are being tested in clinical trials for specific mutation subtypes. Molecular profiling of tumors is guiding therapy decisions and patient selection, enabling more personalized treatment approaches. Immunotherapy, traditionally ineffective in pancreatic cancer due to its “cold” tumor microenvironment, is being re-evaluated through combination strategies involving checkpoint inhibitors, stromal modulation, and oncolytic viruses.

On the diagnostic front, liquid biopsy, circulating tumor DNA (ctDNA), and exosomal RNA analysis are improving early detection and real-time disease monitoring. Endoscopic ultrasound (EUS)-guided biopsy, next-generation sequencing (NGS), and companion diagnostics are becoming routine components of diagnosis and therapy planning. As precision diagnostics and molecular classification become more widespread, pancreatic cancer treatment is moving toward a stratified model where genetic and epigenetic factors guide both systemic and localized interventions.

Which Patient Populations and Regional Markets Are Shaping Demand for Pancreatic Cancer Therapies?

The disease predominantly affects individuals aged 60 and older, with men slightly more at risk than women. Patients with familial cancer syndromes, chronic pancreatitis, diabetes, obesity, and tobacco use history are particularly vulnerable. The aggressive nature of the disease and the limited therapeutic window post-diagnosis underscore the importance of rapid, multidisciplinary treatment protocols involving oncologists, surgeons, and palliative care providers.

North America and Europe are leading in terms of advanced diagnostics, clinical trial activity, and access to combination regimens. The U.S. is at the forefront due to robust funding, academic research collaborations, and inclusion of pancreatic cancer in national cancer strategies. Japan and South Korea are witnessing growing incidence and strong investment in early detection technologies. In developing regions such as Africa, Southeast Asia, and parts of Latin America, access to pancreatic cancer care remains limited, highlighting opportunities for mobile diagnostics, government-sponsored screening, and international support programs.

What Is Driving Long-Term Growth and Scientific Innovation in the Pancreatic Cancer Treatment Market?

The growth in the pancreatic cancer treatment market is driven by increasing disease burden, enhanced genomic understanding, and a surge in R&D focused on overcoming therapeutic resistance. Drug developers are investing in novel modalities such as antibody-drug conjugates (ADCs), epigenetic modulators, T-cell engagers, and nanoparticle-based delivery platforms. Immunotherapy combinations, vaccines targeting neoantigens, and stromal-targeting agents are showing promise in clinical pipelines, despite past disappointments in monotherapy trials.

Strategic innovation is also evident in adaptive clinical trial designs, biomarker-guided recruitment, and global cooperative networks. Pharmaceutical companies are pursuing fast-track and orphan drug designations to accelerate regulatory approvals and secure market exclusivity. Public-private partnerships are funding translational research, while advocacy groups are promoting awareness, early screening, and equitable access. As the oncology landscape evolves toward personalized, biomarker-driven treatment, pancreatic cancer stands out as both a major clinical challenge and a high-potential frontier for therapeutic breakthroughs.

SCOPE OF STUDY:

The report analyzes the Pancreatic Cancer Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy, Targeted Therapy); Indication Type (Exocrine Indication, Endocrine Indication); End-Use (Hospitals End-Use, Oncology Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• AstraZeneca plc
• Bayer AG
• Beigene Ltd.
• Bristol-Myers Squibb Company
• Celgene Corporation
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Genentech, Inc.
• GlaxoSmithKline plc
• Ipsen Pharma
• Lisata Therapeutics
• Merck & Co., Inc.
• Myriad Genetics, Inc.
• Novartis AG
• Oncolytics Biotech Inc.
• Pfizer Inc.
• PharmaCyte Biotech, Inc.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Zydus Cadila

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Pancreatic Cancer Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Late-Stage Diagnosis Throws the Spotlight on Urgent Therapeutic Innovation
  • Increased Investment in Precision Oncology Propels Development of Targeted Pancreatic Cancer Therapies
  • Expansion of Clinical Trials for Immunotherapy Combinations Drives Innovation in Advanced Treatment Protocols
  • Adoption of Next-Generation Sequencing Enhances Molecular Profiling and Personalized Treatment Selection
  • Breakthrough Therapy Designations and Accelerated Approvals Strengthen Pipeline Commercialization
  • Rising Demand for Adjuvant and Neoadjuvant Chemotherapy Expands Use Across Disease Stages
  • Integration of Liquid Biopsy Tools Supports Early Detection and Therapy Monitoring
  • Development of PARP Inhibitors and KRAS-Targeted Therapies Spurs First-in-Class Drug Opportunities
  • Growing Role of Biomarker-Driven Therapies Strengthens Business Case for Companion Diagnostics
  • Increased Global Funding for Pancreatic Cancer Research Supports Translational and Clinical Innovation
  • Emergence of Nanocarrier-Based Drug Delivery Systems Enhances Bioavailability and Tumor Penetration
  • Rising Adoption of Multimodal Therapy Approaches Expands Treatment Complexity and Duration
  • Limited Surgical Eligibility Among Patients Spurs Demand for Effective Non-Invasive Therapies
  • Expansion of Cancer Genomics Platforms Enables Tumor Heterogeneity Analysis and Therapy Optimization
  • Increased Payer Support for High-Cost Oncologics Expands Market Accessibility in Developed Regions
  • Rapid Uptake of Tumor Microenvironment Modulators Drives Growth in Novel Mechanism Approaches
  • Growth in Medical Tourism for Pancreatic Cancer Treatment Propels Demand for Advanced Centers
  • Challenges in Drug Resistance and Toxicity Management Create Demand for Better Tolerability Profiles
  • Establishment of Pancreatic Cancer Centers of Excellence Spurs High-Volume Therapy Adoption
  • Collaborations Between Academic Institutions and Biopharma Companies Accelerate Breakthrough Discovery
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Pancreatic Cancer Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Pancreatic Cancer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Pancreatic Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Hormone Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Oncology Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Oncology Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Oncology Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Exocrine Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Exocrine Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Exocrine Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Endocrine Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Endocrine Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Endocrine Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Pancreatic Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• JAPAN
  • Pancreatic Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• CHINA
  • Pancreatic Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• EUROPE
  • Pancreatic Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Pancreatic Cancer Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Pancreatic Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• FRANCE
  • Pancreatic Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• GERMANY
  • Pancreatic Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Pancreatic Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Pancreatic Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Pancreatic Cancer Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Pancreatic Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Pancreatic Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• INDIA
  • Pancreatic Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Pancreatic Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Pancreatic Cancer Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Pancreatic Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Pancreatic Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Pancreatic Cancer Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Pancreatic Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030
• AFRICA
  • Pancreatic Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Pancreatic Cancer Treatment by Treatment Type - Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Pancreatic Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Hormone Therapy, Surgery, Radiation Therapy and Targeted Therapy for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Pancreatic Cancer Treatment by End-Use - Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Pancreatic Cancer Treatment by End-Use - Percentage Breakdown of Value Sales for Oncology Clinics End-Use, Other End-Uses and Hospitals End-Use for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Pancreatic Cancer Treatment by Indication Type - Exocrine Indication and Endocrine Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Pancreatic Cancer Treatment by Indication Type - Percentage Breakdown of Value Sales for Exocrine Indication and Endocrine Indication for the Years 2015, 2025 & 2030

IV. COMPETITION